Huntington's Disease: A Body Mystery!

Huntington's disease (HD) is a fatal, inherited neurodegenerative disorder primarily caused by an expansion of CAG trinucleotide repeats within the huntingtin gene (HTT) on chromosome 4. Normally, this gene contains a certain number of CAG repeats, which code for the amino acid glutamine. In individuals with HD, this repeat sequence is abnormally elongated.

When the number of CAG repeats exceeds a certain threshold (typically 36 or more), it leads to the production of a mutant huntingtin protein (mHtt). This mHtt protein is misfolded and prone to aggregation, forming toxic inclusions within neurons. The exact mechanisms by which mHtt causes neuronal dysfunction and death are complex and multifaceted, involving transcriptional dysregulation, mitochondrial dysfunction, excitotoxicity, and impaired axonal transport, ultimately leading to the progressive loss of neurons, particularly in the striatum (caudate nucleus and putamen) and cerebral cortex.

HD typically presents with a progressive triad of motor, cognitive, and psychiatric symptoms, though the onset and severity can vary significantly among individuals. Motor symptoms are often the most visible and include chorea, characterized by involuntary, jerky, dance-like movements. However, some individuals, especially those with juvenile onset, may initially exhibit bradykinesia (slowness of movement) and rigidity, mimicking Parkinson's disease.

Other motor issues include dystonia, impaired gait, and difficulties with speech and swallowing. Cognitive decline is also a hallmark, manifesting as executive dysfunction, impaired attention, memory deficits, and eventually dementia. Psychiatric disturbances are common and can precede motor symptoms, including depression, anxiety, apathy, irritability, and psychosis.

The progressive nature of these symptoms profoundly impacts a person's quality of life and independence.

HD follows an autosomal dominant inheritance pattern, meaning an affected individual needs to inherit only one copy of the mutated HTT gene from either parent to develop the disease. This gives affected individuals a 50% chance of passing the mutation to each of their children. A fascinating phenomenon associated with HD is genetic anticipation, where the disease tends to manifest at an earlier age and with greater severity in successive generations.

This is often attributed to the expansion of the CAG repeat length, which can increase with each generation, particularly when passed down through the paternal line. Approximately 10% of cases arise from de novo mutations, where the mutation occurs spontaneously and is not inherited from either parent.

Diagnosis of Huntington's disease is confirmed through genetic testing, which detects the expanded CAG repeat in the HTT gene. This testing can be performed even before symptoms appear, leading to significant ethical considerations. These include the age at which an individual is deemed mature enough to consent to predictive testing, the right of parents to have their children tested, and the complex issues surrounding confidentiality and disclosure of results.

The availability of predictive testing has empowered some individuals to make informed life choices, while for others, it presents a profound psychological burden due to the lack of a cure and the certainty of developing a debilitating disease.

Currently, there is no cure for Huntington's disease, and treatment focuses on managing symptoms and improving quality of life. Tetrabenazine is one of the few medications approved to help control chorea. Antidepressants and antipsychotics are used to manage psychiatric symptoms. Research is actively pursuing disease-modifying therapies.

Strategies include developing small molecules to target mHtt, gene silencing techniques (like RNA interference or antisense oligonucleotides) to reduce mHtt production, and exploring neuroprotective agents. Stem cell therapy and gene editing technologies also hold promise for future regenerative approaches. The global research community is collaborating to accelerate the development of effective treatments and ultimately a cure.